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Background and Aim: We sought to correlate two different measures of gut
permeability [lactulose:mannitol (L:M) and lactulose:rhamnose (L:R)] to the severity of
duodenal histopathology in children with and without elevated antibodies to tissue
transglutaminase (tTG). A secondary objective was to correlate gut permeability
with celiac disease (CD) serology and indices of inflammation and bacterial
product translocation.
Methods: We prospectively randomized children undergoing endoscopy with abnormal
(n = 54) and normal (n = 10) concentrations of circulating antibodies to tTG, to
either L:M or L:R. Biopsies underwent modified Marsh scoring to measure mucosal
injury. Circulating anticore Escherichia coli lipopolysaccharide (LPS) IgG, α-1 acid
glycoprotein, LPS-binding protein, and C-reactive protein concentrations were measured
by enzyme immunoassays.
Results: Of the 54 cases with positive celiac serology, 31 and 69% had modified Marsh
0/1 scores or ≥3a, respectively. Circulating tTG IgA correlated with the modified Marsh
score (p = 0.03). L:R, but not L:M or percent L excreted, differed according to modified
Marsh scores (p = 0.01). There was no significant association between any systemic
marker of inflammation or gut injury, and modified Marsh scores. Concerningly, most
participants had evidence of urinary M before the challenge sugar was administered.
Conclusions: L:R, but not L:M, is associated with modified Marsh scores in
children undergoing small bowel biopsy for suspected CD. Despite increased intestinal
permeability, we see scant evidence of systemic exposure to gut microbes in these
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children. Gut permeability testing with L:R may predict which patients with abnormal
celiac serology will have biopsy evidence for celiac disease and reduce the proportion
of such patients undergoing endoscopy whose Marsh scores are ≤1. M should not be
used as a monosaccharide for permeability testing in children.
Keywords: tissue transglutaminase, dual sugar absorption test, celiac disease, intestinal permeability, Marsh
score

INTRODUCTION

product translocation to determine if these values correlate with
histologic severity, serology, or DSAT signals.

In a healthy gut, tight junctions maintain a barrier between
luminal contents and systemic circulation. The dual sugar
absorption test (DSAT) is the classic measure of human intestinal
permeability, and uses a disaccharide [lactulose (L)] and a
monosaccharide [mannitol (M) or rhamnose (R)] as probes to
test the integrity of the barrier. In this test, people are challenged
orally with these sugars and urine is assayed to determine the
extent to which the sugars are absorbed by the host. However,
the choice, concentrations, and volumes of the sugar solutions,
timing of the urine collection, and methods of assay vary
considerably (1, 2). Furthermore, while M has often been used
as the monosaccharide in these assays, its ubiquity as a food and
supplement additive is problematic as it is often detected in the
urine at baseline [i.e., pre-challenge; (3)]. The ratio of L to R was
recently shown to identify increased intestinal permeability in
children with environmental enteric dysfunction (2). However,
we are unaware of any direct comparison of L and R and L and M
in human conditions with increased intestinal permeability.
Celiac disease (CD) is an immune mediated disorder triggered
by gluten ingestion in genetically predisposed individuals,
which causes villous atrophy and crypt hyperplasia. In North
America, diagnosis of CD relies on finding biopsy changes
in individuals who have elevated celiac serologic markers.
However, discordance between tissue transglutaminase (tTG)
levels and biopsy findings are well-known and often lead to
diagnostic challenges (4). Because CD patients have increased gut
permeability (5), and gut permeability has been recommended
as a non-invasive tool to screen for and monitor the response
to dietary treatment of CD (5–9), we tested the hypothesis that
DSATs using L and R have greater diagnostic precision in CD
than L and M.
Here, we compare the performance of the sugars in children
undergoing endoscopic upper gastrointestinal mucosal biopsy
with elevated and normal concentrations of antibodies to tTG by
prospectively randomizing them to receive either L and M, or L
and R. We then tested the correlation between L:R, L:M, IgA antitTG concentrations, and histologic severity. Given the decreased
gut barrier function in CD, we also anticipated that there
would be systemic evidence of exposure to gut microbes and
inflammation, as has recently been reported (10–15). Therefore,
we additionally assayed indices of inflammation and bacterial

METHODS
Participants
This study was approved by the Washington University in St.
Louis Human Research Protection Office. Informed consent was
obtained from parent(s), and assent from children aged 12 years
and older. Cases, defined as treatment-naïve (i.e., a gluten-free
diet had not yet been started) children ages 0–17.9 years with
suspected CD based on an elevated tTG IgA (n = 50) or tTG
IgG (n = 4) who were referred for endoscopy, were eligible
to participate. Participants were excluded if they had known
inflammatory disorders of the gut or biopsy-proven CD. Controls
were recruited from children ages 0–17.9 years with normal
celiac serology, and no known inflammatory disorders of the
gut. Metadata collected consisted of anthropometrics, laboratory
results, medications, past medical history, current symptoms, and
last oral intake prior to ingesting the sugars.

Celiac Serologies
Because tTG IgA serologies lack universal normalized ratios,
values were related to the upper limit of normal (ULN) used
by the respective laboratories in which each test was performed.
These tests were performed at either St. Louis Children’s Hospital
(66%) or other hospital or commercial laboratories in our
region (34%).

Administration of Dual Sugar Test and
Sample Collection
Participants were categorized as cases or controls and then
randomized (50:50) to receive either an oral solution consisting
of 200 mg of monosaccharide [L-rhamnose (TCI, Portland,
OR, USA) or M (Letco, Decatur, AL, USA)] and 1,000 mg
of disaccharide [L, Cumberland Pharmaceuticals, Nashville,
TN, USA)] in 10 mL of sterile water, prepared by the
St. Louis Children’s Hospital pharmacy. Fasting participants
were provided the solution, and ingestion was monitored
and completed within 5 min. Blood was collected when the
intravenous line was placed for the anesthesia.
Pre- and 1-h post-dosing urines were collected in a sterile bag
or hat depending on the age of the child. If the former was used
for collection, a new bag was placed after dosing. If urine was
produced <30 min after dosing, an additional bag was placed and
this was used for the post-dosing specimen. Start (bag placement)
and end (removal) times of bagged specimens and volume of all
urines collected were recorded. Urines were kept on ice, volumes

Abbreviations: α-1AGP, α-1-acid glycoprotein; CRP, C-reactive protein; CD,
celiac disease; DSAT, dual sugar absorption test; EIAs, enzyme immunoassays;
L, lactulose; LPS, lipopolysaccharide; LBP, LPS binding protein; M, mannitol; R,
rhamnose; tTG, tissue transglutaminase; ULN, upper limit of normal.
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TABLE 1 | Cohort demographics.
Serologic positive participants (n=54)
Biopsy positive [n = 37 (68.5%)]
Girls (%)

Controls (n = 10)

All (n = 64)

Biopsy negative [n = 17 (31.5%)]

31 (83.8)

9 (52.9)

9 (90)

49 (76.6)

9.2 (5.2–12.7)

7.4 (6.5–11.8)

13.0 (11.3–15.7)

9.9 (6.1–12.5)

36 (97.3)

16 (94.1)

10 (100)

62 (96.9)

0

1 (5.9)

0

1 (1.6)

Trisomy 21 (%)

2 (5.4)

1 (5.9)

0

3 (4.7)

Type 1 diabetes (%)

5 (13.5)

4 (23.5)

0

9 (14.1)

Median age (IQR)—yrs.
Race (Caucasian) (%)
Ethnicity (Hispanic)

IgA deficiency (%)

0

1 (5.9)

0

1 (1.6)

Hypothyroidism (%)

4 (10.8)

1 (5.9)

1 (10)

6 (9.4)

Turner syndrome (%)

1 (2.7)

0

0

1 (1.6)

17 (45.9)

9 (52.9)

6 (60)

32 (50.0)

Randomized to L:M (%)

determined, and aliquots were frozen (−80◦ C) until shipped on
dry ice to the Mayo Clinic (Rochester, MN) for assay. Sugars were
quantified in urine using HPLC MS:MS as previously described
(2). These values were used to calculate the concentration of
sugars per mL of urine collected, the percent recovery, and L:M
and L:R. Percent L was calculated across all participants, and not
within groups to which the participants were randomized.

curve on each plate using serial dilutions (1:2,000–1:64,000) of
serum from a patient recently infected with E. coli O157:H7 that
was known to be highly reactive to the core LPS. The reactivity of
the positive control (1:2,000 dilution) was arbitrarily defined as
1,000 EIA units. All samples were run in triplicate.

LBP, α-1AGP, and CRP Assays
We used commercial EIAs to measure concentrations of
circulating LPS binding protein (LBP) (HyCult, Wayne, PA,
USA) and α-1-acid glycoprotein (α-1AGP) and C-reactive
protein (CRP) (R&D Systems, Minneapolis, MN, USA),
according to the manufacturers’ instructions. Values above
the upper limit of quantification for CRP were designated as
5,000 ng/mL.

Biopsies and Interpretation
For each participant with suspected CD two and four biopsies
were obtained from the bulb and the second portion of the
duodenum, respectively.
All pathologists were blinded to the clinical status of the
participants. Two readers initially assigned modified Marsh
scores (16) for each biopsy (hereafter described as Marsh scores).
If the two scores agreed, we considered this reading to be final. If
scores differed by one step (e.g., 3a vs. 3b), the more severe value
was used. If scores differed by more than one step (e.g., 3a vs.
3c), a third pathologist was enlisted to read the slide. If two of the
three scores agreed, this was used. If all three scores varied, the
middle score was used.

Statistics
Group differences were analyzed by the Kruskal-Wallis oneway analysis of variance, with post-hoc testing and correction
for multiple comparisons. Correlation analysis was performed
using Spearman’s r. The significance of differences between
continuous and categorical variables were determined by the
Mann-Whitney and Fisher’s exact test, respectively. Receiver
operating characteristic (ROC) curves and area under the curve
were calculated to determine the ability of L:M and L:R to
distinguish controls from those with Marsh scores of 3a or
higher. All p-values were two sided, and α-value <0.05 was
considered significant. Analyses were performed with Prism
9.3.1 (GraphPad).

Escherichia coli Anticore LPS IgG Enzyme
Immunoassay
We used lipopolysaccharide (LPS) from strain F12 (pSK+),
a TnphoA mutant of Escherichia coli O157:H7 that cannot
express the O157 O-side chain (17) to measure seroreactivity
to generic (core) Enterobacteriaceae LPS. LPS was prepared
and characterized, and enzyme immunoassays (EIAs) were
optimized and performed, as described (18), with the following
changes: each human plasma sample was diluted 1:1,000 in
0.5% BSA in phosphate buffered saline containing 0.05% Tween20 and added to wells in triplicate. Anti-human IgG F(ab’)2 horseradish peroxidase (Millipore, Burlington, MA, USA) at
a 1:10,000 dilution served as the second antibody. Plates
were developed by adding peroxidase substrate tetramethyl
benzidine (ThermoFisher, Waltham, MA, USA) (15 min, room
temperature). Reactions were stopped with 2M H2 SO4 , and
absorbance was measured at 450 nm. We constructed a standard
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RESULTS
Demographics
We enrolled 54 cases (50 and four with elevated tTG IgA or
tTG IgG, respectively), and 10 controls (Table 1). Endoscopies
were performed on controls because of chronic abdominal pain,
nausea, and/or vomiting.

Biopsy Results
In one control participant, the normal endoscopy was
grossly normal, and the rapid urease test was negative, but
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gliadin peptide (DGP) IgA was negative in two of the eight
cases in which it was measured. Anti-DGP IgG was elevated in
each of the four cases in whom a circulating concentration was
determined. The median (IQR) time between type 1 diabetes
diagnosis and elevated serology was 2 (1–219) days.

Sugar Absorption
Six controls and 26 seropositive children were randomized to
L and M, while four controls and 28 seropositive cases were
randomized to L and R (Supplementary Table 3). One 2 yearold randomized to L:M and one 12 year-old randomized to
L:R did not void for over 5 h after ingestion. One 3 year-old
randomized to L:R ingested only half of the L:R solution. These
three participants were removed from analysis of the sugar
probes. Urines were obtained at medians of 65 min (IQR: 60–80)
after ingesting sugar in the L:R group, and 67 min (IQR = 60–73)
in the L:M group (Mann-Whitney, p = ns).
L:R (Kruskal-Wallis p = 0.01) but not L:M (Kruskal-Wallis
p = 0.08) significantly differed according to the Marsh scores
(Figure 2). We also combined cases with Marsh 2–3C scores
and compared those to controls, and again found no significant
association with L:M (adjusted post-hoc Dunn test p = 0.05),
but did find an association with L:R (adjusted post-hoc Dunn
test p = 0.01). Additionally, we calculated the area under the
curve when comparing controls vs. those with Marsh 3a or
higher for both L:M and L:R. The area under the ROC curve
(AUC) for L:R was greater than for L:M (0.89 vs. 0.78). We
also evaluated the sensitivity and specificity of L:M and L:R at
various cutoffs to distinguish controls from those with Marsh
scores of 3a or greater. For L:R the following cutoffs give the
corresponding sensitivity and sensitivity: 0.098 (sensitivity 94%,
specificity 50%), 0.148 (sensitivity 89%, specificity 75%), and
0.262 (sensitivity 78%, specificity 100%). For L:M the following
cutoffs give the corresponding sensitivity and sensitivity: 0.059
(sensitivity 100%, specificity 50%), 0.088 (sensitivity 88%,
specificity 67%), and 0.232 (sensitivity 38%, specificity 100%).
TTG IgA concentrations correlated better with L:R (spearman
r = 0.409, p = 0.03) than with L:M (spearman r = 0.382,
p = 0.04). However, these represent a moderate and weak
correlation, respectively.
We next determined if excretion of single sugars differed
according to Marsh score and found no significant association
(Supplementary Figure 1). Each of the 29 children tested with
L and M who voided before the sugars were administered had
detectable M in the urine. Of the 29 children who received L
and R and produced pre-dosing urine, 13 (45%) had detectable R
(Fisher’s exact test p < 0.0001). The median (interquartile range)
urinary sugar concentrations were considerably greater for M
than for the 13 children in whose urines we detected R [14 µg/mL
(IQR 9.3–27) vs. 0.63 µg /mL (IQR 0.44–1.0), respectively, p
<0.0001; Figure 3].
We asked if subtracting pre-administration urinary M or R
improved L:M or L:R association with Marsh scores. Again,
there was no significant association with L:M (Kruskal-Wallis
p = 0.79), but the L:R ratios (Kruskal-Wallis p = 0.015)
significantly associated (Supplementary Figure 2). We also had
the opportunity to estimate the rate of clearance of baseline M

FIGURE 1 | tTG IgA circulating concentration compared to Marsh score in
cases (n = 50) (not controls). P-value from Kruskal-Wallis. Lines show median
and quartiles. ULN, upper limit of normal.

Helicobacter pylori infection of the stomach was diagnosed
on immunostaining.
The Marsh scores assigned by two pathologists agreed
perfectly in 27 of the 54 cases, and differed by one step in 19.
A third pathologist resolved the scores with greater discrepancies
without knowing the values of the first pair of readings. If two
of the three scores agreed, that value was used (n = 6) (with
agreement defined as being identical). If three different values
were generated, we used the intermediate score (n = 2).
Of the 50 participants with elevated tTG IgA concentrations,
11 (22%) had Marsh 0 and two (4%) had Marsh 1 histology. The
remaining Marsh scores were ≥3a. Each of the 4 case participants
with abnormal tTG IgG concentrations (but normal tTG IgA)
had Marsh 0 (3) or 1 (1) histology. Marsh scores did not vary
according to interval between diagnostic serology and biopsies
(Kruskal-Wallis p = 0.55; Supplementary Table 1). The median
(IQR) intervals between obtaining the tTG IgA and biopsy did
not significantly differ for children with and without type 1
diabetes [34 (17–62) vs. 42 (40–54) days].

Serology
Overall, the circulating tTG IgA concentration significantly
varied with Marsh scores (Figure 1) among cases (p = 0.03).
Ancillary celiac screening tests were obtained in a subset
of participants at the discretion of the treating physician
(Supplementary Table 2). Anti tTG IgG values were normal in
four of 14 cases tested. Anti-endomysial antibody was negative in
one case participant whose Marsh score was 3b. Anti-deamidated
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FIGURE 2 | Dual sugar testing compared to Marsh score in controls (C) and cases. P-value from Kruskal-Wallis. Lines show median and quartiles. (A) Controls and
cases randomized to receive L:M. (B) Controls and cases randomized to L:R.

the biopsy. However, all participants or their caregivers denied
gluten elimination before endoscopy, and the Marsh scores did
not vary according to the interval between serology and biopsy.
Celiac lesions can be patchy in occurrence (4), so sampling
error might have underestimated the degree of mucosal injury.
However, the numbers of biopsies obtained from the bulb and
second portion of the duodenum was uniform and met current
recommendations (4, 21). Furthermore, we cannot be sure that
the ULN cut offs in each assay represented the same antibody
concentration across sites, because each test kit had its own norm
established, and multiples of the ULN might not be equivalent.
This is more likely to be a problem near the lower bounds of
abnormality, but half of the cases in whom the Marsh score was
0/1 had antibody values to tTG at least triple the upper limit
of normal. Finally, we cannot exclude the possibility that the
patients with elevated antibodies to tTG and Marsh scores of 0/1
will eventually develop histologic findings typical of CD (22, 23).
It is noteworthy that four out of the nine children with type
1 diabetes had Marsh 0/1 histology. Fluctuations in circulating
anti-tTG IgA concentrations without evidence of intestinal
changes have been previously described in type 1 diabetes (24).
In any event, the mediocre correlation between Marsh score
and antibody concentrations to tTG at the critical first biopsy
highlights the need for additional methods to predict CD and
inform decisions to perform or forego an endoscopic biopsy.
We sampled urine 1 h after ingestion, a protocol used in
children with environmental enteric dysfunction (2) and children
with diagnosed CD (25), to avoid truncated collection times, but
it is possible that we did not capture the peak of the filtered sugar
columns (26).
Previous studies have raised concern about the presence
of pre-testing (baseline) M (2, 3) in the urine, most likely

by calculating the M in the urine in the post-dosing urine in
the children who were tested with L:R, i.e., those who received
no M. The median clearance was −6.17 µg/min (IQR −15.3
to −1.6). In two children who received R, the concentration
of M actually increased between the pre- and the post-testing
urines. This might be attributed to incomplete voiding in the predosing determination, or surreptitious ingestion of a substance
containing M soon before the pre-dosing sample was obtained.
Using the median M clearance rate, we calculated a corrected
cleared M concentration in the children tested with L:M. Again,
we found no significant association with this corrected L:M and
Marsh score (Kruskal-Wallis p = 0.17; Supplementary Figure 3).

Inflammatory Markers
Blood was obtained at the time of intravenous line placement
for upper endoscopy in nine of the 10 controls and 44 of the 54
cases. There were no significant associations between circulating
E. coli anticore LPS IgG, α-1AGP, LBP, or CRP concentrations
and Marsh score or tTG IgA concentration.

DISCUSSION
We confirmed prior reports that circulating concentrations of
anti tTG IgA in the aggregate correlate with Marsh scores
(19, 20). However, this correlation was far from absolute. For
example, five of the nine participants with circulating antitTG IgA values between one and two times the ULN had
Marsh scores ≥3a, and seven of the 35 children with circulating
anti-tTG IgA concentrations >3 times the ULN had Marsh
scores of 0 or 1. One explanation for the discrepancies between
Marsh scores of 0/1 and tTG IgA positivity could be selfelimination of gluten between the positive serologic test and
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by definition, adults diagnosed with CD will have had longer prebiopsy exposure to gluten. Also unexpectedly, despite increased
intestinal permeability, the children in this study with diet naïve
CD lacked evidence of systemic exposure to LPS. Perhaps this is
related to the lower microbial burden in the proximal small bowel
where CD is believed to be most active.
In conclusion, in the first comparison of L:R and L:M to
identify correlates to disease severity, we demonstrate superiority
of L:R. Our data recommend that L:M testing not be performed.
Further work is needed to improve our ability to predict which
patients with abnormal celiac serology will have biopsy evidence
of active CD, but based on the L:R scores, assessment of
intestinal permeability might reduce unnecessary endoscopies.
Additionally, it will be useful to determine if L:R correlates with
tissue healing after a gluten free diet is initiated, in which case
permeability testing might supplant celiac serology, which can be
problematic as a measure of disease monitoring (27).
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Supplementary Figure 3 | Corrected L:M (adjusted M concentration based on
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and cases. Horizontal lines represent medians and quartiles. P-values
from Kruskal-Wallis.
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Supplementary Table 1 | TTG IgA and biopsy results in cases.

Supplementary Figure 1 | Percent recovery in urine of (A) L in children
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and (C) R in children challenged with L and R. Horizontal lines represent medians
and quartiles. Kruskal-Wallis is not significant for all comparisons.
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